Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nanos C2HC-type zinc finger 1 (NANOS1) is a highly conserved RNA-binding protein that functions as a post-transcriptional regulator, interacting with mRNAs and other RNA-binding proteins (notably Pumilio/PUM2) to repress translation of specific targets essential for germ cell development and maintenance[1][2][3]. NANOS1 contains two CCHC-type zinc finger motifs critical for its RNA-binding and regulatory activities, and is closely linked to male fertility, with mutations causing spermatogenic failure and male infertility[3]. While classified primarily as an RNA-binding regulator/transcription factor, its canonical role in higher eukaryotes is the translational repression in germline cells, and it is not considered a typical receptor, enzyme, or small-molecule drug target[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nanos C2HC-type zinc finger 1 (NANOS1).